Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs provides a comprehensive portfolio of premium anti-IL-1B recombinant antibodies meticulously designed and rigorously validated to empower global researchers in their IL-1B-focused investigations. Our antibodies, characterized by exceptional specificity and sensitivity, exhibit outstanding performance across a spectrum of applications. Backed by robust validation data, these reagents facilitate the smooth progression of our customers’ research endeavors.
IL-1β is primarily generated by immune cells when activated by microbial ligands via Toll-like receptors (TLRs), complement proteins, and other signaling molecules such as TNF or IL-1. This cytokine is important in activating inflammatory responses and contributing to angiogenesis, which promotes tumor formation and metastasis, increasing the risk of cancer progression. As a result, developing treatments that specifically target IL-1β has emerged as a key cancer therapeutic tactic.
Interleukin 1 beta; IL-1β; IL1-BETA; IL1beta; leukocytic endogenous mediator; leukocytic pyrogen; IL1F2; IL-1; mononuclear cell factor; lymphocyte activating factor.
The protein encoded by this gene is a member of the interleukin 1 cytokine family. This cytokine is produced by activated macrophages as a proprotein, which is proteolytically processed to its active form by caspase 1. The encoded protein plays a role in thymocyte proliferation and is involved in the inflammatory response.
Creative Biolabs provides a wide range of recombinant anti-IL1B antibodies that are carefully designed to provide high specificity and affinity and are available in various formats to facilitate a wide range of scientific research and therapeutic endeavors. By utilizing our extensive platform, we provide researchers with cutting-edge tools to advance immunology, oncology, and other relevant areas, as well as to support the development of new therapeutics.
Table 1. Featured anti-IL1B recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
ZG-0498J | Mouse Anti-IL1B Recombinant Antibody (ZG-0498J) | Human | Mouse IgG | WB, IHC, IF, ELISA |
HPAB-N0148-YC | Human Anti-IL1B Recombinant Antibody (clone 048Ab-4) | Human | Human IgG | ELISA |
HPAB-0859-FY | Human Anti-IL1B Recombinant Antibody (HPAB-0859-FY) | Human | Human IgG | Neut |
HPAB-1228-FY | Human Anti-IL1B Recombinant Antibody (HPAB-1228-FY) | Human | Human IgG | Inhib, WB, Neut |
HPAB-0332-FY | Mouse Anti-IL1B Recombinant Antibody (clone 048-Ab-6) | Human | Mouse IgG | In vivo, ELISA |
Creative Biolabs provides a wide selection of recombinant anti-IL1B antibodies that have undergone rigorous quality testing. Our cutting-edge facilities, along with our skilled scientists, meticulously construct each antibody to achieve targeted accuracy against IL1B. Moreover, we ensure that these antibodies have high specificity, strong binding affinity, and optimal performance across a wide range of research applications through applying them through rigorous testing.
Fig.1 WB analysis of anti-IL-1B antibody
(Cat# ZG-0498J, Creative Biolabs).
Fig.2 IHC analysis of anti-IL-1B antibody
(Cat# ZG-0498J, Creative Biolabs).
Fig.3 IF analysis of anti-IL-1B antibody
(Cat# ZG-0498J, Creative Biolabs).
Creative Biolabs produces a consistent supply of superior anti-IL1B antibodies via cutting-edge genetic engineering methods.
Featured Anti-IL1B Recombinant Antibody Production Platforms
Fig.4 Milligram-scale anti-IL1B recombinant antibody production.
Fig.5 Gram-scale anti-IL1B recombinant antibody production.
Creative Biolabs offers an extensive selection of premium anti-IL1B recombinant antibodies in multiple formats, designed to cater to the diverse needs of researchers worldwide.
Fig.7 Full-length anti-IL1B recombinant antibody production and modalities.
Table 2. Public drug targeting IL1B.
Company | Research Phase | Classification | Condition |
Bristol-Myers Squibb (Originator) Novartis (Originator) Radboud Universiteit Nijmegen Universitaet Zuerich Universität Zürich (Universitaet Zuerich) |
Launched - 2009 |
Cancer Immunotherapy Human Monoclonal Antibodies |
Adult onset Still disease Aneurysm, abdominal aortic Arthritis Arthritis, gouty Arthritis, juvenile idiopathic Asthma Autoimmune disease Behcet's disease Cancer, lung (non-small cell) (NSCLC) Cancer, pancreas Cancer, solid tumor Chronic obstructive pulmonary disease (COPD) Cryopyrin-associated periodic syndromes Cytokine release syndrome Diabetes type 1 Diabetes type 2 Familial Mediterranean fever Gout Hypoglycemia Kawasaki disease Macular degeneration Melanoma Mevalonate kinase deficiency Osteoarthritis, knee Other cardiovascular disorders Periodic fever syndrome (autoinflammatory syndrome) Pyoderma gangrenosum Retinopathy, diabetic Rheumatoid arthritis Sarcoidosis, pulmonary Schnitzler syndrome Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) Sickle cell anemia Still disease Synkinesis Thalassemia, beta TNF receptor associated periodic syndrome (TRAPS) Triple negative breast cancer Urticaria, idiopathic Vasculitis Wet macular degeneration (exudative) |
Abbott AbbVie (Originator) |
Phase III |
Bispecific Antibodies Humanized Monoclonal Antibodies |
Hidradenitis suppurativa Osteoarthritis, hand Osteoarthritis, knee Ulcerative colitis |
Flame Biosciences (Originator) | Phase II |
Antibodies Cancer Immunotherapy |
Cancer, lung (non-small cell) (NSCLC) |
Novartis (Originator) | Phase II | Bispecific Antibodies |
Colitis Coronary heart disease Hidradenitis suppurativa Inflammatory disorders Metabolic and nutritional genetic disorders Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) |
Lilly (Originator) | Phase II | Antibodies |
Diabetes type 2 Rheumatoid arthritis |
Amgen (Originator) AstraZeneca MedImmune (AstraZeneca) |
Phase II | Human Monoclonal Antibodies |
Inflammatory disorders Rheumatoid arthritis |
Sunshine Guojian Pharmaceutical (Originator) | Phase I/II | Humanized Monoclonal Antibodies |
Arthritis, juvenile idiopathic Gout Periodic fever syndrome (autoinflammatory syndrome) |
Buzzard Pharmaceuticals Carisma Therapeutics (Originator) Eleven Biotherapeutics (Carisma Therapeutics) |
Phase I/II |
Fusion Proteins Polypeptides, from 41 AA |
Cancer, solid tumor Conjunctivitis, allergic Dry eye |
Tavotek (Originator) | Phase I | Human Monoclonal Antibodies | Inflammatory disorders |
Novartis Servier Xoma (Originator) |
Discontinued |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Acne Acute coronary syndrome Arthritis Arthritis, juvenile idiopathic Behcet's disease Cancer, colorectal Cancer, gastroesophageal junction Cancer, kidney (renal cell carcinoma) Cardiovascular Disorders Dermatomyositis Diabetes type 1 Diabetes type 2 Diabetic nephropathy Ear Disorders Giant cell arteritis Gout Osteoarthritis, hand Pustular psoriasis (generalized) Pyoderma gangrenosum Rheumatoid arthritis Schnitzler syndrome Scleritis Uveitis |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
As a leading antibody manufacturer, Creative Biolabs is devoted to providing a diverse range of high-quality anti-IL1B recombinant antibodies. Please do not hesitate to contact us if you want further information or have any queries about our antibodies.